Data Presentations, Orphan Drug Designations, FDA Applications and Reviews, Drug Market Expansion - Research Report on ACADIA Pharmaceuticals, ViroPharma, Santarus, Cytokinetics, and Exact Sciences

Mon Jun 24, 2013 8:01am EDT

* Reuters is not responsible for the content in this press release.

Data Presentations, Orphan Drug Designations, FDA Applications and Reviews, Drug Market Expansion - Research Report on ACADIA Pharmaceuticals, ViroPharma, Santarus, Cytokinetics, and Exact Sciences

PR Newswire

NEW YORK, June 24, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), ViroPharma Inc. (NASDAQ: VPHM), Santarus, Inc. (NASDAQ: SNTS), Cytokinetics Incorporated (NASDAQ: CYTK), and Exact Sciences Corporation (NASDAQ: EXAS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

ACADIA Pharmaceuticals Inc. Research Report

On June 18, 2013, ACADIA Pharmaceuticals Inc. (ACADIA Pharmaceuticals) presented data from its Phase III program with pimavanserin for Parkinson's disease psychosis (PDP), including data from its pivotal -020 Study and the related, open-label safety extension study, during the poster session at the 17th International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia. Uli Hacksell, Ph.D., CEO of ACADIA Pharmaceuticals, stated, "Data from our open-label safety extension study indicate that long-term administration of pimavanserin is generally safe and well tolerated in PDP patients and suggest that duration of antipsychotic effect may be maintained for longer than the six weeks investigated in our pivotal -020 Study." Hacksell continued, "The overall efficacy and safety profile observed to date shows that pimavanserin has the potential to offer a new treatment option that may provide significant advantages relative to current antipsychotics used off-label for the treatment of PDP." The Full Research Report on ACADIA Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/34b6_ACAD]

--

ViroPharma Inc. Research Report

On June 11, 2013, ViroPharma Inc. (ViroPharma) announced that maribavir has been granted the orphan drug designation by the European Commission. Maribavir is a treatment for cytomegaloviral (CMV) disease in patients with impaired cell mediated immunity. Under EMA protocol, the Orphan Medicinal Product Designation provides 10 years of potential market exclusivity if the product candidate is approved for marketing in the European Union and the orphan designation is maintained. John Watson, ViroPharma's Senior Director of Regulatory Affairs in Europe, commented, "We are very pleased to receive orphan designation for maribavir from the European Commission. This designation recognizes the potential of maribavir to address great unmet medical needs. We commend the European Commission for providing incentives such as this for the development of drugs for rare and life threatening diseases." The Full Research Report on ViroPharma Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/cf37_VPHM]

--

Santarus, Inc.Research Report

On June 18, 2013, Santarus, Inc. (Santarus) and Pharming Group NV announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for review of RUCONEST (recombinant human C1 esterase inhibitor) 50 IU/kg. Gerald T. Proehl, President and CEO of Santarus, said, "RUCONEST is the first recombinant C1 esterase inhibitor developed with the goal of treating the pain and swelling associated with acute HAE attacks. We believe RUCONEST has the potential to be an important new therapeutic option for patients experiencing acute HAE attacks based on the data contained in the BLA from ten clinical studies covering 940 administrations of the drug." The Company expects the US FDA to complete the review of RUCONEST or otherwise respond to the RUCONEST BLA by April 16, 2014. The Full Research Report on Santarus, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/28f6_SNTS]

--

Cytokinetics Incorporated Research Report

On June 12, 2013, Cytokinetics Incorporated (Cytokinetics) and Amgen announced an expansion of their strategic partnership to include Japan. Under the amended agreement, Cytokinetics will give Amgen the license for omecamtiv mecarbil and related compounds to include Japan, which was excluded from the initial terms of collaboration entered in 2006. Cytokinetics is expected to receive $25 million, composed of non-refundable license fee of $15 million and $10 million for Amgen's purchase of the Company's common stock. Robert I. Blum, President and CEO of Cytokinetics, commented, "Our decision to amend the agreement at this time is based on our confidence in the progress of our collaborative development program for omecamtiv mecarbil and on Amgen's recent commitment to expand its business activities in Japan. We look forward to the integration of Japan into our collaboration's global development plan for this promising drug candidate." The Full Research Report on Cytokinetics Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/5a39_CYTK]

--

Exact Sciences Corporation Research Report

On June 10, 2013, Exact Sciences Corporation (Exact Sciences) submitted the final module of the premarket approval (PMA) application for Cologuard, a stool DNA (sDNA) colorectal screening test, to the US Food and Drug Administration (FDA). Kevin T. Conroy, President and CEO of Exact Sciences, stated, "The completion of our PMA submission to the FDA is the most significant milestone in the company's history and a big step forward in helping physicians make the battle against colorectal cancer a winning one." Conroy continued, "I want to thank the tremendous team at Exact Sciences and our collaborators for their outstanding work. We share a passion for delivering our breakthrough colorectal cancer screening test to the physicians and patients who need it. Now, we look forward to continuing to work with the FDA through the review process." The Full Research Report on Exact Sciences Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/984c_EXAS ]

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Reports

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.